APO RESEARCH · REPORT
Human Microbiome
The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
Product & engineering
Understand the product.
The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
Selected research
Industry Research
Human Microbiome Industry Research Report 2026
Market perspective
The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
Read the full market overview
At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share.
Report Scope
This report quantifies the global Human Microbiome market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Human Microbiome.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Microbiome Market by Company
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
Human Microbiome Segment by Type
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Others
Human Microbiome Segment by Application
Treatment
Diagnosis
Human Microbiome Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Microbiome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Microbiome and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Microbiome.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Human Microbiome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Gastrointestinal Tract Human Micobiome
- Urogenital Tract Human Micobiome
- Others
Applications
- Treatment
- Diagnosis
Companies covered
- Vedanta
- Seres Therapeutics
- Second Genome
- Rebiotix
- ActoGeniX
- Enterome BioScience
- AvidBiotics
- 4D Pharma Research Ltd
- Enterologics
- Metabogen
- Metabiomics
- Ritter Pharmaceuticals
- Osel
- Symberix
- Miomics
- Symbiotix Biotherapies
- MicroBiome Therapeutics LLC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Human Microbiome by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Gastrointestinal Tract Human Micobiome
- 2.2.3 Urogenital Tract Human Micobiome
- 2.2.4 Others
- 2.3 Human Microbiome by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Treatment
- 2.3.3 Diagnosis
- 2.4 Assumptions and Limitations
3 Human Microbiome Breakdown Data by Type
- 3.1 Global Human Microbiome Historic Market Size by Type (2021-2026)
- 3.2 Global Human Microbiome Forecasted Market Size by Type (2027-2032)
4 Human Microbiome Breakdown Data by Application
- 4.1 Global Human Microbiome Historic Market Size by Application (2021-2026)
- 4.2 Global Human Microbiome Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Human Microbiome Market Perspective (2021-2032)
- 5.2 Global Human Microbiome Growth Trends by Region
- 5.2.1 Global Human Microbiome Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Human Microbiome Historic Market Size by Region (2021-2026)
- 5.2.3 Human Microbiome Forecasted Market Size by Region (2027-2032)
- 5.3 Human Microbiome Market Dynamics
- 5.3.1 Human Microbiome Industry Trends
- 5.3.2 Human Microbiome Market Drivers
- 5.3.3 Human Microbiome Market Challenges
- 5.3.4 Human Microbiome Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Human Microbiome Players by Revenue
- 6.1.1 Global Top Human Microbiome Players by Revenue (2021-2026)
- 6.1.2 Global Human Microbiome Revenue Market Share by Players (2021-2026)
- 6.2 Global Human Microbiome Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Human Microbiome Head Office and Area Served
- 6.4 Global Human Microbiome Players, Product Type & Application
- 6.5 Global Human Microbiome Manufacturers Established Date
- 6.6 Global Human Microbiome Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Human Microbiome Market Size (2021-2032)
- 7.2 North America Human Microbiome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Human Microbiome Market Size by Country (2021-2026)
- 7.4 North America Human Microbiome Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Human Microbiome Market Size (2021-2032)
- 8.2 Europe Human Microbiome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Human Microbiome Market Size by Country (2021-2026)
- 8.4 Europe Human Microbiome Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Human Microbiome Market Size (2021-2032)
- 9.2 Asia-Pacific Human Microbiome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Human Microbiome Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Human Microbiome Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Human Microbiome Market Size (2021-2032)
- 10.2 South America Human Microbiome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Human Microbiome Market Size by Country (2021-2026)
- 10.4 South America Human Microbiome Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Human Microbiome Market Size (2021-2032)
- 11.2 Middle East & Africa Human Microbiome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Human Microbiome Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Human Microbiome Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Vedanta
- 12.1.1 Vedanta Company Information
- 12.1.2 Vedanta Business Overview
- 12.1.3 Vedanta Revenue in Human Microbiome Business (2021-2026)
- 12.1.4 Vedanta Human Microbiome Product Portfolio
- 12.1.5 Vedanta Recent Developments
- 12.2 Seres Therapeutics
- 12.2.1 Seres Therapeutics Company Information
- 12.2.2 Seres Therapeutics Business Overview
- 12.2.3 Seres Therapeutics Revenue in Human Microbiome Business (2021-2026)
- 12.2.4 Seres Therapeutics Human Microbiome Product Portfolio
- 12.2.5 Seres Therapeutics Recent Developments
- 12.3 Second Genome
- 12.3.1 Second Genome Company Information
- 12.3.2 Second Genome Business Overview
- 12.3.3 Second Genome Revenue in Human Microbiome Business (2021-2026)
- 12.3.4 Second Genome Human Microbiome Product Portfolio
- 12.3.5 Second Genome Recent Developments
- 12.4 Rebiotix
- 12.4.1 Rebiotix Company Information
- 12.4.2 Rebiotix Business Overview
- 12.4.3 Rebiotix Revenue in Human Microbiome Business (2021-2026)
- 12.4.4 Rebiotix Human Microbiome Product Portfolio
- 12.4.5 Rebiotix Recent Developments
- 12.5 ActoGeniX
- 12.5.1 ActoGeniX Company Information
- 12.5.2 ActoGeniX Business Overview
- 12.5.3 ActoGeniX Revenue in Human Microbiome Business (2021-2026)
- 12.5.4 ActoGeniX Human Microbiome Product Portfolio
- 12.5.5 ActoGeniX Recent Developments
- 12.6 Enterome BioScience
- 12.6.1 Enterome BioScience Company Information
- 12.6.2 Enterome BioScience Business Overview
- 12.6.3 Enterome BioScience Revenue in Human Microbiome Business (2021-2026)
- 12.6.4 Enterome BioScience Human Microbiome Product Portfolio
- 12.6.5 Enterome BioScience Recent Developments
- 12.7 AvidBiotics
- 12.7.1 AvidBiotics Company Information
- 12.7.2 AvidBiotics Business Overview
- 12.7.3 AvidBiotics Revenue in Human Microbiome Business (2021-2026)
- 12.7.4 AvidBiotics Human Microbiome Product Portfolio
- 12.7.5 AvidBiotics Recent Developments
- 12.8 4D Pharma Research Ltd
- 12.8.1 4D Pharma Research Ltd Company Information
- 12.8.2 4D Pharma Research Ltd Business Overview
- 12.8.3 4D Pharma Research Ltd Revenue in Human Microbiome Business (2021-2026)
- 12.8.4 4D Pharma Research Ltd Human Microbiome Product Portfolio
- 12.8.5 4D Pharma Research Ltd Recent Developments
- 12.9 Enterologics
- 12.9.1 Enterologics Company Information
- 12.9.2 Enterologics Business Overview
- 12.9.3 Enterologics Revenue in Human Microbiome Business (2021-2026)
- 12.9.4 Enterologics Human Microbiome Product Portfolio
- 12.9.5 Enterologics Recent Developments
- 12.10 Metabogen
- 12.10.1 Metabogen Company Information
- 12.10.2 Metabogen Business Overview
- 12.10.3 Metabogen Revenue in Human Microbiome Business (2021-2026)
- 12.10.4 Metabogen Human Microbiome Product Portfolio
- 12.10.5 Metabogen Recent Developments
- 12.11 Metabiomics
- 12.11.1 Metabiomics Company Information
- 12.11.2 Metabiomics Business Overview
- 12.11.3 Metabiomics Revenue in Human Microbiome Business (2021-2026)
- 12.11.4 Metabiomics Human Microbiome Product Portfolio
- 12.11.5 Metabiomics Recent Developments
- 12.12 Ritter Pharmaceuticals
- 12.12.1 Ritter Pharmaceuticals Company Information
- 12.12.2 Ritter Pharmaceuticals Business Overview
- 12.12.3 Ritter Pharmaceuticals Revenue in Human Microbiome Business (2021-2026)
- 12.12.4 Ritter Pharmaceuticals Human Microbiome Product Portfolio
- 12.12.5 Ritter Pharmaceuticals Recent Developments
- 12.13 Osel
- 12.13.1 Osel Company Information
- 12.13.2 Osel Business Overview
- 12.13.3 Osel Revenue in Human Microbiome Business (2021-2026)
- 12.13.4 Osel Human Microbiome Product Portfolio
- 12.13.5 Osel Recent Developments
- 12.14 Symberix
- 12.14.1 Symberix Company Information
- 12.14.2 Symberix Business Overview
- 12.14.3 Symberix Revenue in Human Microbiome Business (2021-2026)
- 12.14.4 Symberix Human Microbiome Product Portfolio
- 12.14.5 Symberix Recent Developments
- 12.15 Miomics
- 12.15.1 Miomics Company Information
- 12.15.2 Miomics Business Overview
- 12.15.3 Miomics Revenue in Human Microbiome Business (2021-2026)
- 12.15.4 Miomics Human Microbiome Product Portfolio
- 12.15.5 Miomics Recent Developments
- 12.16 Symbiotix Biotherapies
- 12.16.1 Symbiotix Biotherapies Company Information
- 12.16.2 Symbiotix Biotherapies Business Overview
- 12.16.3 Symbiotix Biotherapies Revenue in Human Microbiome Business (2021-2026)
- 12.16.4 Symbiotix Biotherapies Human Microbiome Product Portfolio
- 12.16.5 Symbiotix Biotherapies Recent Developments
- 12.17 MicroBiome Therapeutics LLC
- 12.17.1 MicroBiome Therapeutics LLC Company Information
- 12.17.2 MicroBiome Therapeutics LLC Business Overview
- 12.17.3 MicroBiome Therapeutics LLC Revenue in Human Microbiome Business (2021-2026)
- 12.17.4 MicroBiome Therapeutics LLC Human Microbiome Product Portfolio
- 12.17.5 MicroBiome Therapeutics LLC Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst